Immunotherapeutic strategies for COVID-19
| Kinase inhibitors |
| Tofacitinib, baricitinib, ruxolitinib, others |
| Targeted therapy |
| Inhibitors of interleukin 1 (IL-1), IL-6, tumor necrosis factor, and granulocyte macrophage colony-stimulating factor; interferon gamma |
| Tolerogenic therapies |
| T-cell regulators, low-dose IL-2 |
| Cellular therapies |
| Natural killer cell therapies, antiplasmacytoid dendritic cell, others |
| Passive therapy |
| Intravenous immune globulin, immune plasma, specific antibodies |
| Nonspecific therapies |
| Glucocorticoids, calcineurin inhibitors, mammalian target of rapamycin inhibitors |